Veraxa Biotech AG (VRXA) called an Extraordinary General Meeting for December 10, 2026, at 11:00 AM at Walder Wyss AG in Zurich; doors open at 10:30 AM. The Board of Directors proposes that shareholders elect KPMG AG as statutory auditor for the 2026 business year, after BDO AG announced its resignation as auditor.
Veraxa Biotech AG - Post de-SPAC (VRXA) director Marc Gruninger reported two direct purchases of Ordinary Shares: 9,133 shares at $1.00 per share on October 28, 2026, and 867 shares at $0.98 per share on October 27, 2026. No Rule 10b5-1 plan is reported for these purchases.
Veraxa Biotech AG - Post de-SPAC (VRXA) director Christoph Samuel Ziegler purchased 30,000 ordinary shares on October 20, 2026, at $1.09 per share. His reported direct holdings after the transaction were 37,932 ordinary shares. No Rule 10b5-1 plan is reported.
VRXA (Veraxa Biotech AG) presented first in vivo proof-of-concept and additional in vitro data for its BiTAC-ADC technology at the 17th World ADC Congress. The company reported strong tumor regression in a xenograft breast cancer model after a single systemic dose of 3 mg/kg, with no observed decrease in body weight in the treatment arm.
The release says a construct with one non-targeted component showed no significant effect; a control ADC using the same conjugation and linker-payload technology and drug-antibody ratio performed similarly. Additional in vitro results reported discrimination between cancer and healthy cells, a requirement for both constructs to be co-targeted to the tumor site, and no release of active toxins in the periphery. The company cautions that preclinical results may not predict later-stage trials or results in humans.
Veraxa Biotech AG - Post de-SPAC (VRXA) has a new Section 16 reporting person: Chief Financial Officer Willener Raju Sudir filed an initial statement of beneficial ownership on Form 3. The filing reports no transactions and does not list any reportable holdings or derivative positions at this time.
Veraxa Biotech AG (VRXA) filed a prospectus supplement updating its Form F-1 to cover the issuance of up to 19,436,739 Ordinary Shares upon exercise of warrants at US$11.50 per share and the potential resale of up to 6,786,739 Private Warrants and up to 120,295,385 Ordinary Shares by selling securityholders.
The company’s Ordinary Shares trade on the Nasdaq Global Market under “VRXA” at $1.53 and its Warrants on the Nasdaq Capital Market under “VRXAW” at $0.08 as of September 3, 2026. Veraxa will receive cash only if warrants are exercised for cash. Veraxa also highlights its status as an emerging growth company and foreign private issuer, which allows reduced U.S. reporting and different corporate governance practices. Separately, Veraxa appointed Raju Willener as Chief Financial Officer and principal financial and accounting officer, bringing more than three decades of global finance and capital markets experience.
Veraxa Biotech AG (VRXA) filed a prospectus supplement for the resale, from time to time, of up to 25,000,000 ordinary shares by Lincoln Park Capital Fund, LLC under an existing purchase agreement. Veraxa may sell Ordinary Shares to Lincoln Park at its discretion and could receive up to $50,000,000 in gross proceeds from such sales, but will receive no proceeds from Lincoln Park’s resale of the registered shares.
The company’s Ordinary Shares and warrants trade on Nasdaq under the symbols VRXA and VRXAW, which closed at $1.53 and $0.08 on September 3, 2026. Veraxa is an emerging growth company and a foreign private issuer, and follows home-country corporate governance practices that may provide fewer protections than Nasdaq standards for U.S. domestic companies.
Separately, Veraxa appointed Raju Willener as Chief Financial Officer and principal financial and accounting officer, effective immediately. He brings more than three decades of international finance and capital markets experience, including oversight of investment portfolios exceeding CHF 30 billion in assets under management, to support the company’s antibody-based cancer therapy pipeline and BiTAC® platform.
Veraxa Biotech AG (VRXA) announced the appointment of Raju Willener as Chief Financial Officer, effective September 4, 2026. He will serve as the company’s principal financial and accounting officer and report to CEO and Co-Founder Christoph Antz, Ph.D.
The company highlights that Mr. Willener brings more than three decades of international experience across investment banking, corporate finance, asset management and strategic leadership, including oversight of investment portfolios exceeding CHF 30 billion in assets under management. Veraxa positions this hire as strengthening its capital markets and financial strategy capabilities as it advances its BiTAC-based oncology pipeline. The company also acknowledges the contributions of former CFO Carl von Halem.
Veraxa Biotech AG (VRXA) director Oliver Rolf Baumann reported an indirect open-market purchase of Veraxa ordinary shares. On 2026-08-27, an entity associated with him, Akira Holding AG, purchased 50,000 Ordinary Shares at $1.50 per share. Following this transaction, Akira Holding AG holds 5,773,618 Veraxa ordinary shares that Baumann may be deemed to beneficially own.
Veraxa Biotech AG (VRXA) reported that Chief Executive Officer and director Christoph Rudiger Antz purchased 5,000 Ordinary Shares on 2026-08-27 in a non-derivative, open-market or private transaction at a price of $1.53 per share. Following this transaction, he directly owns 5,000 Ordinary Shares.